NEW YORK (GenomeWeb) – 23andMe has raised $250 million in funding, the consumer genomics firm announced today.

23andMe said it plans to use the money to grow its customer base, expand its therapeutics group, and invest in its genetic research platform. With this latest funding, 23andMe has raised $491 million from a range of investors, including technology and health science companies, angel investors, and venture capital firms.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.